Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product–receptor axis (Q44103908)

29 November 2017

title

Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product-receptor axis (English)

1 reference

29 November 2017

Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product–receptor axis (English)

1 reference

https://api.crossref.org/works/10.1016/J.PHRS.2011.02.003

24 November 2024

1

Takanori Matsui

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21320599

24 November 2024

author name string

Yuri Nishino

2

1 reference

29 November 2017

Masayoshi Takeuchi

3

1 reference

29 November 2017

Sho-ichi Yamagishi

4

1 reference

29 November 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21320599

24 November 2024

publication date

12 February 2011

1 reference

full work available at URL

29 November 2017

https://api.elsevier.com/content/article/PII:S1043661811000533?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.PHRS.2011.02.003

https://api.elsevier.com/content/article/PII:S1043661811000533?httpAccept=text/plain

24 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.PHRS.2011.02.003

24 November 2024

published in

Pharmacological Research

1 reference

29 November 2017

volume

63

1 reference

29 November 2017

issue

5

1 reference

29 November 2017

page(s)

383-388

1 reference

Vildagliptin in clinical practice: a review of literature.

29 November 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1016/J.PHRS.2011.02.003

The role of incretins in glucose homeostasis and diabetes treatment

24 November 2024

2

1 reference

https://api.crossref.org/works/10.1016/J.PHRS.2011.02.003

The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose

24 November 2024

3

1 reference

https://api.crossref.org/works/10.1016/J.PHRS.2011.02.003

Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes

24 November 2024

4

1 reference

https://api.crossref.org/works/10.1016/J.PHRS.2011.02.003

Combination therapy with nateglinide and vildagliptin improves postprandial metabolic derangements in Zucker fatty rats

24 November 2024

5

1 reference

https://api.crossref.org/works/10.1016/J.PHRS.2011.02.003

Recent progress in advanced glycation and diabetic vascular disease: role of advanced glycation end product receptors

24 November 2024

6

1 reference

https://api.crossref.org/works/10.1016/J.PHRS.2011.02.003

Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications

24 November 2024

7

1 reference

https://api.crossref.org/works/10.1016/J.PHRS.2011.02.003

Novel inhibitors of glycation and AGE formation

24 November 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.PHRS.2011.02.003

The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature

24 November 2024

9

1 reference

https://api.crossref.org/works/10.1016/J.PHRS.2011.02.003

Regulation of advanced glycation end product (AGE)-receptor (RAGE) system by PPAR-gamma agonists and its implication in cardiovascular disease

24 November 2024

10

1 reference

https://api.crossref.org/works/10.1016/J.PHRS.2011.02.003

Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy

24 November 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.PHRS.2011.02.003

The role of AGEs in cardiovascular disease

24 November 2024

12

1 reference

https://api.crossref.org/works/10.1016/J.PHRS.2011.02.003

Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications

24 November 2024

13

1 reference

https://api.crossref.org/works/10.1016/J.PHRS.2011.02.003

Receptor for advanced glycation end products (RAGE): a novel therapeutic target for diabetic vascular complication

24 November 2024

14

1 reference

https://api.crossref.org/works/10.1016/J.PHRS.2011.02.003

Smooth muscle cell pathophysiology and advanced glycation end products (AGEs).

24 November 2024

15

1 reference

https://api.crossref.org/works/10.1016/J.PHRS.2011.02.003

Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression

24 November 2024

16

1 reference

https://api.crossref.org/works/10.1016/J.PHRS.2011.02.003

Pigment-epithelium-derived factor suppresses expression of receptor for advanced glycation end products in the eye of diabetic rats

24 November 2024

19

1 reference

https://api.crossref.org/works/10.1016/J.PHRS.2011.02.003

Pigment epithelium-derived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression

24 November 2024

20

1 reference

https://api.crossref.org/works/10.1016/J.PHRS.2011.02.003

Pigment epithelium-derived factor inhibits advanced glycation end product-elicited mesangial cell damage by blocking NF-kappaB activation

24 November 2024

21

1 reference

https://api.crossref.org/works/10.1016/J.PHRS.2011.02.003

Irbesartan inhibits advanced glycation end product (AGE)-induced proximal tubular cell injury in vitro by suppressing receptor for AGEs (RAGE) expression.

24 November 2024

22

1 reference

https://api.crossref.org/works/10.1016/J.PHRS.2011.02.003

Advanced glycation endproducts inhibit prostacyclin production and induce plasminogen activator inhibitor-1 in human microvascular endothelial cells

24 November 2024

23

1 reference

https://api.crossref.org/works/10.1016/J.PHRS.2011.02.003

Nifedipine, a calcium channel blocker, inhibits advanced glycation end product (AGE)-elicited mesangial cell damage by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gamma activation.

24 November 2024

24

1 reference

https://api.crossref.org/works/10.1016/J.PHRS.2011.02.003

Pigment epithelium-derived factor prevents advanced glycation end products-induced monocyte chemoattractant protein-1 production in microvascular endothelial cells by suppressing intracellular reactive oxygen species generation

24 November 2024

25

1 reference

https://api.crossref.org/works/10.1016/J.PHRS.2011.02.003

Advanced glycation end products inhibit de novo protein synthesis and induce TGF-beta overexpression in proximal tubular cells

24 November 2024

26

1 reference

https://api.crossref.org/works/10.1016/J.PHRS.2011.02.003

Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells

24 November 2024

27

1 reference

https://api.crossref.org/works/10.1016/J.PHRS.2011.02.003

Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin

24 November 2024

28

1 reference

https://api.crossref.org/works/10.1016/J.PHRS.2011.02.003

Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats

24 November 2024

29

1 reference

https://api.crossref.org/works/10.1016/J.PHRS.2011.02.003

Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes

24 November 2024

30

1 reference

https://api.crossref.org/works/10.1016/J.PHRS.2011.02.003

24 November 2024

Identifiers

1 reference

29 November 2017

1 reference